Arcturus Therapeutics (ARCT) Projected to Announce Quarterly Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Arcturus Therapeutics to announce earnings of ($0.6804) per share and revenue of $8.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. The firm had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.11 million. On average, analysts expect Arcturus Therapeutics to post ($3.48) EPS for the current fiscal year and ($3.59) EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $9.54 on Wednesday. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $17.96. The stock has a 50-day moving average of $13.44 and a 200-day moving average of $9.01.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ARCT. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. BTIG Research decreased their price objective on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Zacks Research raised Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Finally, Citigroup raised Arcturus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $8.00 to $20.00 in a research note on Thursday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.29.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.